Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Rosenheck, Robert A.
2007.
Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics.
British Journal of Psychiatry,
Vol. 191,
Issue. 3,
p.
238.
Arranz, M J
and
de Leon, J
2007.
Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.
Molecular Psychiatry,
Vol. 12,
Issue. 8,
p.
707.
Tandon, Rajiv
Belmaker, R.H.
Gattaz, Wagner F.
Lopez-Ibor, Juan J.
Okasha, Ahmed
Singh, Bruce
Stein, Dan J.
Olie, Jean-Pierre
Fleischhacker, W. Wolfang
and
Moeller, Hans-Juergen
2008.
World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.
Schizophrenia Research,
Vol. 100,
Issue. 1-3,
p.
20.
Patnaik, Meeta
Renda, Matthew J.
Athanasiou, Maria C.
and
Reed, Carol R.
2008.
The Role of Pharmacogenetics in Treating Central Nervous System Disorders.
Experimental Biology and Medicine,
Vol. 233,
Issue. 12,
p.
1504.
Naber, Dieter
and
Lambert, Martin
2009.
The CATIE and CUtLASS Studies in Schizophrenia.
CNS Drugs,
Vol. PAP,
Issue. ,
Ginovart, Nathalie
and
Kapur, Shitij
2009.
Dopamine Handbook.
p.
540.
Roerig, James L.
Steffen, Kristine J.
Mitchell, James E.
Crosby, Ross D.
and
Gosnell, Blake A.
2009.
An Exploration of the Effect of Modafinil on Olanzapine Associated Weight Gain in Normal Human Subjects.
Biological Psychiatry,
Vol. 65,
Issue. 7,
p.
607.
Picchioni, Marco M.
and
Dazzan, Paola
2009.
Clinical significance of neurological abnormalities in psychosis.
Advances in Psychiatric Treatment,
Vol. 15,
Issue. 6,
p.
419.
Emsley, Robin
2009.
Drugs in development for the treatment of schizophrenia.
Expert Opinion on Investigational Drugs,
Vol. 18,
Issue. 8,
p.
1103.
Susatia, Frandy
and
Fernandez, Hubert H.
2009.
Drug-induced parkinsonism.
Current Treatment Options in Neurology,
Vol. 11,
Issue. 3,
p.
162.
Littrell, Jill
and
Lyons, Peter
2010.
Pediatric Bipolar Disorder: An issue for Child Welfare.
Children and Youth Services Review,
Vol. 32,
Issue. 7,
p.
965.
Ginovart, Nathalie
and
Kapur, Shitij
2010.
The Dopamine Receptors.
p.
431.
Bandelow, Borwin
Chouinard, Guy
Bobes, Julio
Ahokas, Antti
Eggens, Ivan
Liu, Sherry
and
Eriksson, Hans
2010.
Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study.
The International Journal of Neuropsychopharmacology,
Vol. 13,
Issue. 03,
p.
305.
El-Khalili, Nizar
Joyce, Mark
Atkinson, Sarah
Buynak, Robert J.
Datto, Catherine
Lindgren, Petter
and
Eriksson, Hans
2010.
Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
The International Journal of Neuropsychopharmacology,
Vol. 13,
Issue. 07,
p.
917.
Perr, Jane V.
and
Ettinger, Alan B.
2011.
The Neuropsychiatry of Epilepsy.
p.
165.
Khan, Arifulla
Joyce, Mark
Atkinson, Sarah
Eggens, Ivan
Baldytcheva, Irina
and
Eriksson, Hans
2011.
A Randomized, Double-Blind Study of Once-Daily Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients With Generalized Anxiety Disorder.
Journal of Clinical Psychopharmacology,
Vol. 31,
Issue. 4,
p.
418.
Stein, Dan J.
Bandelow, Borwin
Merideth, Charles
Olausson, Bengt
Szamosi, Johan
and
Eriksson, Hans
2011.
Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8‐week placebo‐controlled studies.
Human Psychopharmacology: Clinical and Experimental,
Vol. 26,
Issue. 8,
p.
614.
van Harten, Peter N.
and
Tenback, Diederik E.
2011.
Pathophysiology, Pharmacology, and Biochemistry of Dyskinesia.
Vol. 98,
Issue. ,
p.
187.
Bakker, P. Roberto
de Groot, Izaäk W.
van Os, Jim
van Harten, Peter N.
and
Priller, Josef
2011.
Long-Stay Psychiatric Patients: A Prospective Study Revealing Persistent Antipsychotic-Induced Movement Disorder.
PLoS ONE,
Vol. 6,
Issue. 10,
p.
e25588.
Núñez, Francisco Portillo
Uriarte, Laura Rodríguez
Villaverde, Cristina Alonso
Movillán, Enrique Vadillo
Losantos, Juan Miguel Rodríguez
and
Martín, Jose Miguel Cebamanos
2012.
Parkinsonismo secundario a la asociación de metronidazol y quetiapina.
Psiquiatría Biológica,
Vol. 19,
Issue. 2,
p.
62.